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Abstract
Background: With more than 600,000 mortalities each year, colorectal cancer (CRC) is the third most commonly
diagnosed type of cancer worldwide. Recently, mechanisms involving noncoding RNAs have been implicated in the
development of CRC.
Methods: We examined expression levels of lncRNA CRNDE and miR-181a-5p in 64 cases of CRC tissues and cell
lines by qRT-PCR. Gain-of-function and loss-of-function assays were performed to examine the effect of CRNDE and
miR-181a-5p on proliferation and chemoresistance of CRC cells. Using fluorescence reporter and western blot
assays, we also explored the possible mechanisms of CRNDE in CRC cells.
Results: In this study, we found that the expression levels of the CRNDE were upregulated in CRC clinical tissue
samples. We identified microRNA miR-181a-5p as an inhibitory target of CRNDE. Both CRNDE knockdown and miR-
181a-5p overexpression in CRC cell lines led to inhibited cell proliferation and reduced chemoresistance. We also
determined that β-catenin and TCF4 were inhibitory targets of miR-181a-5p, and that Wnt/β-catenin signaling was
inhibited by both CRNDE knockdown and miR-181a-5p overexpression. Significantly, we found that the repression
of cell proliferation, the reduction of chemoresistance, and the inhibition of Wnt/β-catenin signaling induced by
CRNDE knockdown would require the increased expression of miR-181a-5p.
Conclusions: Our study demonstrated that the lncRNA CRNDE could regulate the progression and
chemoresistance of CRC via modulating the expression levels of miR-181a-5p and the activity of Wnt/β-catenin
signaling.
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Background
With more than 600,000 mortalities each year, colorectal
cancer (CRC) is the third most commonly diagnosed type
of cancer worldwide [1, 2]. Like many other cancer types,
the development of CRC is a process characterized by mul-
tiple stages and involves accumulation of both genetic and
epigenetic changes [3]. An extensive body of recent re-
search has revealed that the initiation and progression of
CRC are regulated by a number of cellular signaling path-
ways, including the TGFβ/SMAD pathway, the p53 path-
way, the EGFR/MAPK pathway, the PI3K-Akt pathway,
and the Wnt/β-catenin pathway [4]. Recently, mechanisms
involving noncoding RNAs have also been implicated in
the development of CRC [5–8].
Based on size, noncoding RNAs (ncRNAs) can be cat-
egorized into small ncRNAs (<200 nt) and long ncRNAs
(>200 nt). Small ncRNAs, including microRNAs, have
been demonstrated to function primarily via regulating
gene expression, including modulating mRNA stability
and repressing protein translation [9]. A number of
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microRNAs were found to act as oncogenes or tumor
suppressor genes by previous reports [10–12]. Charac-
terized by lack of cross species conservation [13, 14], the
mechanism of action for long ncRNAs (lncRNAs) is
poorly understood. However, rapidly accumulating evi-
dence has consistently indicated that lncRNAs play es-
sential roles in a variety of cellular processes, and
therefore may contribute to the development of cancer
and other human diseases [15, 16].
The lncRNA Colorectal Neoplasia Differentially
Expressed (CRNDE) is transcribed from chromosome 16
on the strand opposite to the adjacent IRX5 gene [17].
The expression levels of CRNDE were originally found to
be increased in CRC [17], and were also upregulated in a
number of solid and hematopoietic cancer types, including
liver [18], pancreatic [19], ovarian [20], kidney cancer [21],
glioma [22], and leukemia [23]. Besides cancer progres-
sion, the CRNDE gene also participated in the regulation
of neuronal differentiation, gametogenesis and other de-
velopmental processes [24]. In addition, the mouse ortho-
log of CRDNE was demonstrated to be involved in the
maintenance of cellular pluripotency [25]. Although there
was some preliminary evidence that CRNDE could inter-
act with chromatin-modifying complexes to affect epigen-
etic regulation of gene expression [26], the mechanism by
which CRNDE plays its role, particularly in the develop-
ment of CRC, has not yet been elucidated.
In the present study, we found that the expression levels
of the lncRNA CRNDE were upregulated in CRC clinical
tissue samples. We identified microRNA miR-181a-5p as
a target for CRNDE. The expression of miR-181a-5p was
inhibited by CRNDE. Knockdown of CRNDE and overex-
pression of miR-181a-5p in CRC cell lines both led to
inhibited cell proliferation and reduced chemoresistance.
We also determined that β-catenin and TCF4 were inhibi-
tory targets of miR-181a-5p, and that Wnt/β-catenin
signaling was inhibited by both CRNDE knockdown and
miR-181a-5p overexpression. Significantly, we found that
the repression of cell proliferation, the reduction of
chemoresistance, and the inhibition of Wnt/β-catenin
signaling in CRC cells induced by CRNDE knockdown all
required the activity of miR-181a-5p. Taken together, our
study demonstrated that the lncRNA CRNDE could
regulate the progression and chemoresistance of CRC via
modulating the expression levels of miR-181a-5p and the
activity of the Wnt/β-catenin signaling pathway.
Methods
Clinical samples
The procedures of this study were approved by the
Institutional Review Board of Harbin Medical Univer-
sity. Written informed consent was obtained from 64
participants. Fresh colorectal cancer tissues and paired
adjacent normal specimens were collected by surgical
resection. The patients with colorectal cancer had received
neither chemotherapy nor radiotherapy prior to section.
Pathological diagnostics for colorectal cancer were deter-
mined by three pathologists. The clinical characteristics in
64 CRC patients is presented in the Table 1.
TCGA analysis
The RNA-seq data of 157 tumor and 30 matched normal
samples were downloaded from The Cancer Genome
Atlas (TCGA) Data Portal (https://tcga-data.nci.nih.gov/
tcga/). The expression of lncRNAs was quantified by the
customized data analysis pipeline that including the steps
of quality control, alignment, and expression quantifica-
tion. We utilized UCSC hg19 as the Homo sapiens refer-
ence genome and gene model for read mapping and
quantification. The correlation analysis was performed
based on Pearson product-moment correlation coefficient.
Cell culture and treatment
Human CRC cell lines HCT116 and SW480 were cul-
tured in Dulbecco’s Modified Eagle Medium with 4.5 g/
L glucose (DMEM; Gibco BRL, Grand Island, NY, USA)
containing 10% fetal bovine serum (FBS; Gibco BRL)
Table 1 Correlation between CRNDE expression and clinical
characteristics of CRC
Factor Number CRNDE expression P
Low High
Age (y) 0.117
<60 23 15 8
≥60 41 17 24
Gender 0.123
Male 39 16 23
Female 25 16 9
Tumor location 0.617
Colon 31 14 17
Rectum 33 18 15
Tumor size (cm) 0.002**
< 5 29 21 8
≥ 5 35 11 24
Histologic grade 0.001**
Grade 1 + 2 51 31 20
Grade 3 + 4 13 1 12
Lymph node metastasis 0.011*
Yes 37 13 24
No 27 19 8
Distant metastasis 0.750
M0 52 27 25
M1 12 5 7
*P < 0.05, **P < 0.01
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and 1% antibiotic/antimycotic solution. Cells were main-
tained at 37 °C in an atmosphere of 5% CO2 and 95%
room air.
LncRNA CRNDE siRNA, control siRNA, miR-181a-5p
and miR-181a-5p inhibitor were all obtained from Gene-
Pharma (Shanghai, China). 5-fluorouracil (5-Fu) and oxali-
platin (Oxa) were all purchased from Sigma Aldrich (St
Louis, MO, USA). Lipofectamine™ 3000 (Life Technolo-
gies, San Diego, CA, USA) was used for cell transfection
according to manufacturer’s instructions. After 48 h of
transfection, cells were treated different concentration of
5-Fu (0, 3, 6, 12, 24 and 48 μg/ml) or Oxa (0, 4, 8, 16, 32
and 64 μg/ml).
qRT-PCR
Total RNA was extracted from colorectal cancer cell
lines and patient specimens using TRIzol reagent (Life
Technologies) according to the manufacturer’s manual.
One microgram of total RNA was used as template for
cDNA synthesis using a PrimeScript RT Reagent Kit
with cDNA Eraser (Takara Biotech, Dalian, China) and
qRT-PCR was performed using SYBR Premix Ex Taq
(Takara Biotech). MiRNA expression were performed in
triplicate using SYBR PrimeScriptTM miRNA RT-PCR
Kit (Takara Biotech). All qRT-PCR assays was performed
on an ABI 7900 system (Applied Biosystems, Foster City,
CA, USA). Expression levels of genes or miRNA were
normalized to that of the housekeeping gene glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) or SNORD6
(U6 snRNA). 2−ΔΔCt method was applied for calculation
of relative levels of genes and miRNA expression.
RNA fluorescence in-situ hybridization (FISH)
RNA FISH assays were performed to observe CRNDE lo-
cation. CRC cells were fixed by 4% formaldehyde for
10 min at room temperature and then permeablized using
0.5% Triton X-100 for 30 min. Afterwards, the cells were
washed 3 × for 5 min in PBS and then Hybridized with
cDNA probe labeled fluorochromes Cy3 (green).
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
MTT assay was used for cell proliferation and cell inhib-
ition rate analysis. Colorectal cancer cells were seeded in
96-well plate at a density of 1 × 103 cells per well. After
treatment, the cells were washed twice with phosphate
buffer saline (PBS). Then, 10 μL of MTT dye (5 mg/mL)
was added to the wells at different time points. After 4 h
incubation, 100 μL of dimethyl sulfoxide (DMSO) was
added to each well to dissolve the formazan crystals and
the absorbance was measured at 590 nm.
Colony formation assay
HCT116 and SW480 cells (0.5 × 103 cells per well) were
seeded in a six-well plate and cultured for 10 days after
treatment. Colonies were then fixed with 10% formalde-
hyde for 10 min and stained for 5 min with 0.5% crystal
violet. Then the number of colonies was counted using
ImageJ and images were taken under Olympus micro-
scope (Tokyo, Japan).
Bromodeoxyuridine (BrdU) assay
Colorectal cancer cell proliferation was determined by
BrdU assay using a BrdU kit (Abcam, Cambridge, MA,
USA) according to the manufacturer’s instructions. Cells
were growing on cover slips and incubated with BrdU
during DNA synthesis for 1 h followed by staining with
an anti-BrdU antibody after treatment. Images were ac-
quired using an Olympus camera under a microscope.
Establishment of 5-Fu resistant cells
5-Fu resistant colorectal cells were generated by con-
tinuous exposure to increasing concentrations of 5-Fu
(from 5 to 30 μg/ml) with repeated subculture until fully
resistant to 5-Fu. Cells were first cultured in growing
medium with 5 μg/ml 5-Fu for two months and the con-
centration of 5-Fu increased 5 μg/ml every two months.
Luciferase assay
CRNDE wild type with potential miR-181a-5p binding
sites or mutant of each sites were generated and fused to
the luciferase reporter vector psi-CHECK-2 (Promega,
Madison, WI, USA). The full-length wild-type (WT) 3′
untranslated region (UTR) containing the predicted
miR-181a-5p targeting site, and mutant (MUT) 3′-UTR
of β-catenin and TCF4 were amplified and cloned into
the psi-CHECK-2 vector. HEK293T cells were placed on
a 24-well plate and grew till 80% confluence. Cells were
then co-transfected with luciferase plasmids and miR-
181a-5p or control miRNA. After 48 h transfection, fire-
fly and renilla luciferase activities were measured with a
Dual-Luciferase Reporter Assay System (Promega).
Pull-down assays
Pull-down assays were performed as described previ-
ously [27]. Briefly, S1-CRNDE and S1-CRNDE mutant
were generated, and cotransfected with or without miR-
181a-5p inhibitor. After 48 h of transfection, cells were
harvested and washed by PBS for two times, then cross-
linked in 0.37% formaldehyde, incubated in ice-cold lysis
buffer (150 mM NaCl, 10 mM Hepes, 3 mM MgCl2,
10% glyceral, 1% NP-40, 2 mM DTT, 1 mM PMSF, 1 ×
protenase inhibitor (Sigma), 10 ul RNase inhibitor (pro-
mega)). The cell lysate was precleaned in agarose beads
(Santa Cruz Biotechnology) at 4 °C for 1 h, then incu-
bated and rotated in streptavidin beads (Thermo Fisher
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Scientific, San Jose, CA, USA) at 4 °C for 3 h. The
streptavidin beads were collected, washed in elution
buffer (50 mM Hepes, 5 mM EDTA, 100 mM NaCl,
1% SDS, 10 mM DTT). The beads were heated at
70 °C for 45 min. miR-181a-5p expression was exam-
ined by qRT-PCR.
Western blot analysis
Total proteins were prepared from colorectal cells using
RIPA buffer (50 mm Tris-HCl, 150 mm NaCl, 1 mm
EDTA, 0.1% SDS, 1% Triton X-100, 0.1% sodium deoxy-
cholate) with proteinase inhibitor cocktail (Boster,
Wuhan, China). The lysates were centrifuged at
12,000 rpm for 15 min at 4 °C and protein concentration
was measured by BCA kit (Beyotime Biotechnology,
Beijing, China). Equal quantities of protein were electro-
phoresed through a 10% sodium dodecyl sulfate/poly-
acrylamide gel and transferred to a nitrocellulose
membranes (Millipore, Billerica, MA). The membranes
were blocked and then incubated with β-catenin, TCF4,
Cyclin D1, Axin2 and GAPDH (Santa Cruz Biotechnol-
ogy) overnight at 4 °C. Subsequently, the membranes
were incubated with a HRP-conjugated anti-mouse or
-rabbit secondary antibody (Santa Cruz Biotechnology)
at room temperature for 1 h. The protein bands were vi-
sualized using a chemiluminescence reagent (ECL) kit
(Beyotime Biotechnology).
Statistics
The data are expressed as the mean ± standard error
(SD) from at least three independent experiments. The
differences between two groups were analyzed using Stu-
dent’s t test or a one-way ANOVA when more than two
groups were compared. Correlations between miRNA
expression and its targets were analyzed by the Spear-
man’s test. A value of P < 0.05 was considered statisti-
cally significant. All statistial analyses were performed
using GraphPad software version 5.0 (GraphPad Soft-
ware, CA, USA).
Results
CRNDE expression is elevated in CRC tissue
In order to investigate the relevance of lncRNA CRNDE
in CRC development, we first sought to determine the
levels of CRNDE expression form TCGA database. As
shown in Fig. 1a, expression of CRNDE was significantly
upregulated in CRC tissues (P < 0.001). We also com-
plied gene expression data from the GSO/GDS4385
Fig. 1 CRNDE expression is elevated in CRC tissue. a Expression levels of CRNDE analyzed from data retrieved from the TCGA database in CRC
patients (P <0.001). b Expression levels of CRNDE analyzed from GSO/GDS4385 (P < 0.01). c Expression levels of CRNDE as determined by qRT-PCR
in 64 clinical CRC samples compared to those in adjacent normal tissue samples (P < 0.001). d CRNDE expression in six CRC cell lines compared
with normal colorectal tissue pool. *P < 0.05, ***P < 0.01 and ***P < 0.001. e Kaplan-Meier analysis of the association between GRIM-19 expression
and the survival in 64 clinical CRC patients. P < 0.001
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database, and confirmed that the expression levels of
CRNDE were increased in CRC tissue (Fig. 1b, P <
0.001). Next, CRNDE expression was examined by qRT-
PCR on samples from 64 clinical CRC patients com-
pared to adjacent normal tissue and elevated CRNDE
expression was observed (Fig. 1c, P < 0.001). We then
performed qRT-PCR to analyze CRNDE expression in
six CRC cell lines (Caco2, HT29, HCT15, HCT116,
SW620 and SW480). As compared to 3 normal CRC
sample, overexpressed levels of CRNDE expression was
seen in all CRC cell line (Fig. 1d). Furthermore, we per-
formed Kaplan-Meier survival analysis of the association
between CRNDE expression and the survival in 64 clin-
ical CRC patients. As shown in Fig. 1e, high expression
of CRNDE significantly shorterned CRC patient survival
time. We next detected CRNDE location by RNA FISH
assays and found nuclear location of CRNDE in CRC
cells (Additional file 1). These results were consistent
with previous findings in another cohort of patients [17],
and suggested that CRNDE might be involved in the
regulation of CRC development.
CRNDE binds to miR-181a-5p and represses its expression
To determine the mechanism of action for CRNDE in
CRC development, we identified miR-181a-5p as a po-
tential target of CRNDE with LncBase Predicted v.2 of
DIANA tools. There are two putative binding sites of
CRNDE at the regions of 43–35 and 578–583 on miR-
181a-5p (Fig. 2a). We generated wild type CRNDE lucif-
erase plasmids containing potential miR-181a-5p bind-
ing sites and their mutant of each site. These plasmids
was co-transfected with miR-181a-5p into HEK293T
cells, respectively, and then luciferase assays were per-
formed. As shown in Fig. 2b, miR-181a-5p could reduce
wild type and mutant-2 CRNDE luciferase activity. But it
can’t affect mutant-1 activity. The results indicated that
miR-181a-5p binds transcript position (43–50) of
CRNDE. In tissue samples from 64 clinical CRC pa-
tients, we determined that the expression levels of miR-
181a-5p were significantly downregulated (Fig. 2c), a
trend opposite to that of CRNDE. To examine whether
miR-181a-5p was indeed a target of CRNDE, we first
knocked down CRNDE expression in two independent
CRC cell lines, HCT116 and SW480 cells, by siRNA
transfection. The efficacy of knockdown was confirmed
by qRT-PCR analysis (Fig. 2d). In both CRNDE knock-
down cell lines, we observed elevated expression levels
of miR-181a-5p (Fig. 2e). We next increased wild type
and mutant CRNDE expression in CRC cell lines
(Fig. 2f ), we found that the expression levels of miR-
181a-5p were significantly inhibited by wild type CRNDE
but not by mutant (Fig. 2g). Importantly, overexpression
(Additional file 2a) or knockdown (Additional file 2b) of
miR-181a-5p did not cause any change in the expression
levels of CRNDE (Additional file 2c and d), indicating
that miR-181a-5p was downstream of CRNDE. To fur-
ther investigate whether CRNDE and miR-181a-5p bind-
ing together, we performed pull-down assays. As shown
in Fig. 2h, CRNDE was confirmed binding with miR-
181a-5p and this binding was inhibited by miR-181a-5p
inhibitor. Mutation of CRNDE binding sequence with
miR-181a-5p inhibited miR-181a-5p precipitation. The
inhibitory regulation of miR-181a-5p by CRNDE was
further corroborated by the analysis of clinical samples.
We also observed inverse correlation between the ex-
pression levels of CRNDE and miR-181a-5p in CRC tis-
sue samples (Fig. 2i, r = −0.632, P < 0.001). Taken
together, our data supported that miR-181a-5p was an
inhibitory target of CRNDE in both CRC cells and tissue
samples.
CRNDE promotes CRC cell proliferation and
chemoresistance
To investigate the function of CRNDE on CRC cell pro-
liferation, we first knocked down the expression of
CRNDE in two CRC cell lines, HCT116 and SW480
cells. We then performed MTT cell proliferation assay
on these cells. We found that knockdown of CRNDE in
both cell lines significantly inhibited cell proliferation
(Fig. 3a). Significantly, overexpression of miR-181a-5p in
both HCT116 and SW480 cells was able to recapitulate
the inhibitory effects on cell proliferation conferred by
CRNDE knockdown (Fig. 3b). In contrast, CRNDE over-
expression and miR-181a-5p knockdown both led to in-
creased cell proliferation in CRC cells (Additional file 3a
and b). We also performed additional assays to confirm
the regulation of cell proliferation by CRNDE and miR-
181a-5p. In crystal violet staining assay, colony forma-
tion of CRC cells was inhibited by knockdown of
CRNDE (Fig. 3c) and by overexpression of miR-181a-5p
(Fig. 3d). Consistently, we observed significantly less ac-
tively divided cells in BrdU assay with CRNDE knock-
down (Fig. 3e) and miR-181a-5p overexpression
(Fig. 3f ). These data collectively indicated that CRNDE
promoted CRC cell proliferation.
As previous research demonstrated that noncoding
RNAs are involved in the chemoresistance of cancer cells
[28], we hypothesized that CRNDE and miR-181a-5p
could also regulate the chemoresistance of CRC cells. To
test this hypothesis, we treated CRNDE knockdown or
miR-181a-5p overexpressing CRC cells with an increasing
serial of concentrations of 5-Fu. As expected, 5-Fu led to
cell growth inhibition in a dose-dependent manner. We
found that CRNDE knockdown (Fig. 4a) and miR-181a-5p
overexpression (Fig. 4b) appeared to increase the sensitiv-
ity of CRC cells to 5-Fu treatment and therefore further
inhibited cell growth. Conversely, CRNDE overexpression
(Additional file 4a) and miR-181a-5p knockdown
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(Additional file 4b) resulted in decreased 5-Fu sensitivity,
and partially alleviate the growth inhibition of CRC cells
induced by 5-Fu treatment. These results were further
confirmed by the treatment of another chemotherapy
drug Oxa. Consistently, CRNDE knockdown (Fig. 4c) and
miR-181a-5p overexpression (Fig. 4d) led to increased
sensitivity of CRC cells to Oxa treatment, and CRNDE
overexpression (Additional file 4c) and miR-181a-5p
knockdown (Additional file 4d) led to decreased Oxa sen-
sitivity of CRC cells. Importantly, we also found that in
Fig. 3 CRNDE knockdown and miR-181a-5p overexpression inhibit CRC cell proliferation. a MTT cell proliferation assays performed in HCT116 and
SW480 cells transfected with siR-CRNDE or siR-control, or in HCT116 and SW480 cells transfected with miR-181a-5p or a control microRNA (miR-
control). b colony formation assays performed in HCT116 and SW480 cells transfected with siR-CRNDE or siR-control, or in HCT116 and SW480
cells transfected with miR-181a-5p or miR-control. c BrdU assay performed in HCT116 and SW480 cells transfected with siR-CRNDE or siR-control,
or in HCT116 and SW480 cells transfected with miR-181a-5p or miR-control. *P < 0.05, **P < 0.01
(See figure on previous page.)
Fig. 2 CRNDE binds to miR-181a-5p and represses its expression. a Schematic illustration of the predicted binding sites between CRNDE and miR-181a-5p,
and mutation of potential miR-181a-5p binding sequence in CRNDE. b Luciferase assays in 293 T cells transfected CRNDE wild type or mutants with miR-
181a-5p (*P< 0.05). c Expression levels of miR-181a-5p as determined by qRT-PCR in 64 CRC samples compared to those in adjacent normal tissue samples
(P< 0.001). d Expression levels of CRNDE and emiR-181a-5p as determined by qRT-PCR in HCT116 and SW480 cells transfected with siRNA targeting
CRNDE (siR-CRNDE) or a control siRNA (siR-control) (*P< 0.05, ***P< 0.001). f Expression levels of CRNDE and gmiR-181a-5p as determined by qRT-PCR in
HCT116 and SW480 cells transfected with plasmids overexpressing wild type, mutant CRNDE or an empty vector (*P< 0.05, ***P< 0.001). h HEK293T were
transfected with CRNDE, S1-CRNDE or S1-CRNDE mutant with or without miR-181a-5p inhibitor, then pull-down assays were performed (*P< 0.05). i Inverse
correlation between the expression levels of CRNDE and those of miR-181a-5p in 64 CRC samples (r=−0.632, P< 0.001)
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chemoresistant CRC cells, the expression levels of CRNDE
were significantly increased (Fig. 4e), while the expression
levels of miR-181a-5p were decreased (Fig. 4f). Taken to-
gether, these data indicated that CRNDE increased the re-
sistance of CRC cells against chemotherapy drugs.
MiR-181a-5p targets β-catenin/TCF4 and inhibits Wnt/β-
catenin signaling
We next used publicly available algorithms (DIANA
TOOLS and microRNA.org) to identify potential targets
of miR-181a-5p. From TarBase v7.0 of DIANA TOOLS
[29], we noticed that intracellular signal transducer β-
catenin and transcriptional factor TCF4 in the Wnt/β-ca-
tenin signaling pathway were downregulated in human
umbilical vein endothelial cells (HUVEC) after miR-181a-
5p transfection (Fig. 5a). We then sought to confirm this
prediction in the context of CRC cells. Based on the pre-
dicted binding sites of miR-181a-5p, we generated β-
catenin and TCF4 3′-UTR wild type (WT) and mutant
(MUT) luciferase reporter plasmids (Fig. 5b). We then
performed luciferase reporter assays by co-transfecting lu-
ciferase reporter plasmids with miR-181a-5p. We found
that the overexpression of miR-181a-5p decreased the lu-
ciferase activity driven by the wild type 3′-UTRs of both
β-catenin and TCF4, but caused no change in the lucifer-
ase activity driven by the mutant 3′-UTRs of both β-
catenin and TCF4 (Fig. 5c). In contrast, knockdown of
miR-181a-5p increased the luciferase activity driven by
the wild type 3′-UTRs of both β-catenin and TCF4, but
not by the mutant 3′-UTRs of both β-catenin and TCF4
(Additional file 5a). Furthermore, the protein levels of
both β-catenin and TCF4 in CRC cells were reduced by
miR-181a-5p overexpression (Fig. 5d), and were increased
by miR-181a-5p knockdown (Additional file 5b). The in-
hibition of β-catenin and TCF4 by miR-181a-5p was also
confirmed in clinical samples. In 64 CRC tissue samples,
we were able to establish inverse correlation between the
expression levels of miR-181a-5p and β-catenin (r =
−0.562, P < 0.001), and between those of miR-181a-5p and
TCF4 (r = −0.518, P < 0.001) (Fig. 5e). Since β-catenin and
Fig. 4 CRNDE knockdown and miR-181a-5p overexpression repress CRC cell chemoresistance. a MTT cell proliferation assay performed in HCT116 and
SW480 cells transfected with siRNA targeting CRNDE or a control siRNA and treated with the indicated concentrations of 5-Fu. b MTT cell proliferation
assay performed in HCT116 and SW480 cells transfected with miR-181a-5p or a control microRNA and treated with the indicated concentrations of
5-Fu. c MTT cell proliferation assay performed in HCT116 and SW480 cells transfected with siR-CRNDE or a control siRNA and treated with the indicated
concentrations of Oxa. d MTT cell proliferation assay performed in HCT116 and SW480 cells transfected with miR-181a-5p or miR-control and treated
with the indicated concentrations of Oxa. e Expression levels of CRNDE and f miR-181a-5p as determined by qRT-PCR in 5-Fu resistant HCT116 and
SW480 cells. *P < 0.05
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TCF4 are important components in the Wnt/β-catenin
signaling pathway, we next sought to determine whether
miR-181a-5p could affect the activity of Wnt/β-catenin
signaling. With TOP/FOP luciferase activity assay, we
found that overexpression of miR-181a-5p significantly
inhibited the activity of Wnt/β-catenin signaling (Fig. 5f),
and that knockdown of miR-181a-5p stimulated the activ-
ity of Wnt/β-catenin signaling (Additional file 5c). Finally,
we found that the levels of downstream target genes of
the Wnt/β-catenin signaling pathway, including Cyclin D1
and Axin2, were substantially decreased by miR-181a-5p
overexpression in CRC cells (Fig. 5g).
CRNDE promotes CRC cell proliferation and
chemoresistance via miR-181a-5p mediated regulation of
Wnt/β-catenin signaling
Our previous results demonstrated that CRNDE knock-
down and miR-181a-5p overexpression led to inhibition
of CRC cell proliferation and chemoresistance. Since
CRNDE inhibited miR-181a-5p expression, and miR-
181a-5p inhibited Wnt/β-catenin signaling, it is possible
that the inhibition of CRC cell proliferation and
chemoresistance induced by CRNDE knockdown was
due to increased miR-181a-5p expression and conse-
quent inhibition of Wnt/β-catenin signaling. To test this
Fig. 5 MiR-181a-5p targets β-catenin/TCF4 and inhibits Wnt/β-catenin signaling. a Expression levels of β-catenin and TCF4 shown as downregulated in
HUVEC overexpressing miR-181a-5p from TarBase v7.0 database of DIANA TOOLS. b Schematic illustration of the predicted miR-181a-5p binding sites with
the 3′-UTR of β-catenin and TCF4. c Luciferase activity assay performed in HEK293 cells co-transfected with miR-181a-5p and luciferase reporter plasmids
driven by either wild type (WT) or mutant (MUT) 3′-UTR of β-catenin and TCF4 that was devoid of miR-181a-5p binding activity. d The protein levels of β-
catenin and TCF4 as determined by Western blot analysis in HCT116 and SW480 cells transfected with miR-181a-5p or miR-control. e Inverse correlation
between the expression levels of miR-181a-5p and those of β-catenin (r= −0.562, P< 0.001), and between the expression levels of miR-181a-5p and those
of TCF4 (r= −0.518, P< 0.001) in 64 CRC samples. f TOP/FOP luciferase activity in HCT116 and SW480 cells transfected with miR-181a-5p or a miR-control.
g The protein levels of Cyclin D1 and Axin2 as determined by Western blot analysis in HCT116 and SW480 cells transfected with miR-181a-5p or
miR-control. *P< 0.05
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hypothesis, we knocked down β-catenin or TCF4, re-
spectively, and performed MTT cell proliferation assays
in the presence of 5-Fu or Oxa. As showed in Additional
file 6, inhibition of Wnt/β-catenin signaling resulted in
CRC cell chemoresistance. We next concomitantly
knocked down the expression of miR-181a-5p in
CRNDE knockdown CRC cells. Significantly, while
CRNDE knockdown led to significantly inhibited CRC
cell proliferation, simultaneous miR-181a-5p knockdown
completely reversed the inhibition of cell proliferation
(Fig. 6a), indicating that the increased levels of miR-
181a-5p expression were essential for the cell prolifera-
tion inhibition induced by CRNDE knockdown.
Consistently, miR-181a-5p knockdown also completely
reversed the inhibition of colony formation of CRC cells
caused by CRNDE knockdown (Fig. 6b). These pheno-
types were not only observed in HCT116 cells, but also
in SW480 cells (Additional file 7a and b). With regard to
the regulation of CRC cell chemoresistance by CRNDE,
we found that the increased sensitivity of CRC cells to
both 5-Fu (Fig. 6c and Additional file 7c) and Oxa
(Fig. 6d and Additional file 7d) treatment induced by
CRNDE knockdown was completely abolished by simul-
taneous miR-181a-5p knockdown, indicating that the in-
creased levels of miR-181a-5p expression were also
essential for the increased sensitivity of CRC cells to
Fig. 6 Regulation of CRC cell proliferation, chemoresistance and Wnt/β-catenin signaling by CRNDE requires miR-181a-5p. a MTT cell proliferation
assay, b colony formation assay, c MTT cell proliferation assay under the treatment of the indicated concentrations of 5-Fu or d Oxa, e The protein
levels of β-catenin and TCF4 as determined by Western blot analysis, and f TOP/FOP luciferase activity assay performed in HCT116 cells transfected with
siR-CRNDE or siR-control simultaneously with inhibitors of miR-181a-5p or miR-control. *P < 0.05
Han et al. Molecular Cancer  (2017) 16:9 Page 10 of 13
chemotherapy drugs induced by CRNDE knockdown.
Importantly, we also sought to determine whether
CRNDE regulated Wnt/β-catenin signaling in CRC cells,
and whether this regulation was dependent on miR-
181a-5p. As expected, knockdown of CRNDE led to de-
creased protein levels of both for β-catenin and TCF4,
presumably via upregulation of miR-181a-5p. However,
simultaneous knockdown of miR-181a-5p was able to re-
verse the repression of β-catenin and TCF4 expression
(Fig. 6e and Additional file 7e). In addition, CRNDE
knockdown inhibited the activity of Wnt/β-catenin sig-
naling, as evidenced by TOP/FOP luciferase activity, but
this inhibition was abolished by simultaneous miR-181a-
5p knockdown (Fig. 6f and Additional file 7f ), suggesting
that CRNDE regulated Wnt/β-catenin signaling in CRC
cells via modulating the expression of miR-181a-5p. Col-
lectively, these data strongly support the hypothesis that
CRNDE promotes CRC cell proliferation and chemore-
sistance via miR-181a-5p mediated regulation of Wnt/β-
catenin signaling (Fig. 7).
Discussion
In this study, we focused our research on the regulation
of CRC progression and chemoresistance by the lncRNA
CRNDE. We started our investigation by examining the
expression levels of CRNDE in CRC clinical samples.
We found significant increase in CRNDE expression in
CRC samples, and this result was also corroborated by
the analysis of available data in the TCGA database. In
fact, CRNDE has been shown to be upregulated in nu-
merous types of cancers [18–23], but the molecular
mechanism of CRNDE in the regulation of cancer pro-
gression was not clear.
We identified miR-181a-5p as a target of CRNDE by
bioinformatics prediction based on sequence complemen-
tarity. Changes in CRNDE expression led to correspond-
ing changes in the expression levels of miR-181a-5p, but
changes in miR-181a-5p expression did not affect the ex-
pression levels of CRNDE, suggesting that miR-181a-5p
was downstream of CRNDE. The inverse correlation be-
tween the expression levels of CRNDE and miR-181a-5p
in both clinical samples and the TCGA database further
validated the target relation between the two non-coding
RNAs. To study the functional roles of CRNDE and miR-
181a-5p in regulating CRC progression and chemoresis-
tance, we performed experiments in two independent
CRC cell lines. This design would ensure that any result in
our study would not be restricted to a single line of cells.
We found that knockdown of CRNDE led to repressed
cell proliferation and reduced chemoresistance, which was
consistent with the oncogenic roles of CRNDE revealed
by previous studies. Also, the fact that loss of endogenous
CRNDE had inhibitory effects on CRC cell proliferation
suggested that the presence of CRNDE would be required
for the progression of CRC at physiological levels. Import-
antly, we also found that overexpression of miR-181a-5p
induced the same phenotypes as CRNDE knockdown,
which was once again consistent with the inhibitory regu-
lation of miR-181a-5p by CRNDE.
The involvement of miR-181a-5p in cancer development
has been studied by many groups, and the results were
controversial. MiR-181a-5p was found to be up-regulated
in pancreatic cancer and breast cancer [30, 31], and other
miR-181 family members were up-regulated in hepatocel-
lular cancer stem cells [32, 33]. However, other studies
demonstrated that miR-181a was down-regulated in gli-
omas [34] and aggressive chronic lymphocytic leukemia
[35]. Even in CRC development, miR-181a could function
as both oncogene and tumor suppressor. MiR-181a was
found to be associated with poor prognosis of colorectal
cancer [36, 37]. MiR-181a also promoted tumor growth
and liver metastasis in colorectal cancer by targeting the
tumor suppressor WIF-1 [38]. In contrast, the expression
levels of miR-181a were shown to increase during the pro-
gression from non-neoplasia to dysplasia in inflammatory
bowel disease-associated CRC, whereas decrease when
dysplasia develops into cancer [39]. Our study appears to
support a tumor suppressor role for miR-181a-5p, in
terms of cell proliferation and chemoresistance. The
mechanism of action of miR-181a-5p was initially investi-
gated via target prediction. We identified β-catenin and
TCF4 as inhibitory targets of miR-181a-5p. This predic-
tion was confirmed by multiple lines of evidence. First,
miR-181a-5p was able to inhibit the wild type 3′-UTR ac-
tivities of β-catenin and TCF4 in a luciferase assay, but
had no effect in the same assay on the activities of the mu-
tant 3′-UTR devoid of miR-181a-5p binding ability.
Fig. 7 Schematic representation of Wnt/β-catenin signaling involved
in regulation of CRNDE and miR-181a-5p
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Second, miR-181a-5p overexpression reduced the expres-
sion of endogenous β-catenin and TCF4, and thereby ini-
hibited the activity of Wnt/β-catenin signaling.
Although our study did not provide direct evidence
whether the changes in Wnt/β-catenin signaling activity
were required for the regulation of CRC cell prolifera-
tion and chemoresistance by CRNDE and miR-181a-5p,
numerous previous studies have implicated Wnt/β-ca-
tenin signaling in the regulation of cell proliferation and
chemoresistance (summarized in [40]). In this context, it
is reasonable for us to conclude that CRNDE promotes
CRC cell proliferation and chemoresistance via miR-
181a-5p mediated regulation of Wnt/β-catenin signaling.
From clinical characteristics analysis, high CRNDE leads
to more Lymph node metastasis. Further investigation
for CRNDE relative to CRC metastasis is needed.
Conclusions
In our investigation, we have established a signaling cascade
involving CRNDE and miR-181a-5p in the regulation of
Wnt/β-catenin signaling, cell proliferation and the che-
moresistance of CRC cells. We postulated that if restoration
of increased miR-181a-5p expression levels by a miRNA in-
hibitor could abolish the phenotypes induced by CRNDE
knockdown, it would indicate that miR-181a-5p was re-
quired for CRNDE to regulate Wnt/β-catenin signaling,
CRC cell proliferation and chemoresistance. Our study
maybe provide an efficient therapeutic approach for CRC
treatments.
Additional files
Additional file 1: Nuclear location of CRNDE in CRC cancer cells. RNA
FISH assays were performed in HCT116 and SW480 cells for CRNDE
expression. (TIF 2436 kb)
Additional file 2: Effects of miR-181a-5p on CRNDE expression. a Expression
levels of miR-181a-5p as determined by qRT-PCR in HCT116 and SW480 cells
transfected with miR-181a-5p or miR-control. b Expression levels of miR-181a-5p
as determined by qRT-PCR in HCT116 and SW480 cells transfected with a
microRNA inhibitor targeting miR-181a-5p (miR-181a-5p inhibitor) or a control
microRNA inhibitor (miR-control inhibitor). c Expression levels of CRNDE as
determined by qRT-PCR in HCT116 and SW480 cells transfected with miR-181a-
5p or miR-control. d Expression levels of CRNDE as determined by qRT-PCR in
HCT116 and SW480 cells transfected with a microRNA inhibitor targeting miR-
181a-5p or miR-control inhibitor. **P< 0.01, ***P< 0.001. (TIF 2575 kb)
Additional file 3: CRNDE overexpression and miR-181a-5p knockdown
promote CRC cell proliferation. a MTT cell proliferation assay performed
in HCT116 and SW480 cells transfected with plasmids overexpressing
CRNDE or a control vector. b MTT cell proliferation assay performed in
HCT116 and SW480 cells transfected with miR-181a-5p inhibitor or miR-
control inhibitor. *P < 0.05. (TIF 1506 kb)
Additional file 4: CRNDE overexpression and miR-181a-5p knockdown
promote CRC cell chemoresistance. a MTT cell proliferation assay performed
in HCT116 and SW480 cells transfected with plasmids overexpressing
CRNDE or a control vector and treated with the indicated concentrations of
5-Fu. b MTT cell proliferation assay performed in HCT116 and SW480 cells
transfected with miR-181a-5p inhibitor or miR-control inhibitor and treated
with the indicated concentrations of 5-Fu. c MTT cell proliferation assay
performed in HCT116 and SW480 cells transfected with plasmids
overexpressing CRNDE or a control vector and treated with the indicated
concentrations of Oxa. d MTT cell proliferation assay performed in HCT116
and SW480 cells transfected with miR-181a-5p inhibitor or miR-control
inhibitor and treated with the indicated concentrations of Oxa. *P < 0.05.
(TIF 2723 kb)
Additional file 5: Inhibition of miR-181a-5p promotes Wnt/β-catenin
signaling. a Luciferase activity assay performed in HEK293 cells co-transfected
with a microRNA inhibitor targeting miR-181a-5p and luciferase reporter
plasmids driven by either WT or MUT 3′-UTR of β-catenin and TCF4 that was
devoid of miR-181a-5p binding activity. b The protein levels of β-catenin and
TCF4 as determined by Western blot analysis in HCT116 and SW480 cells
transfected with miR-181a-5p inhibitor or miR-control inhibitor. c TOP/FOP
luciferase activity in HCT116 and SW480 cells transfected with a microRNA
inhibitor targeting miR-181a-5p or a control microRNA inhibitor. *P< 0.05.
(TIF 2515 kb)
Additional file 6: Wnt/β-catenin signaling is required for CRC cell
chemoresistance. a β-catenin was silenced in HCT116 and SW480 cells. The
protein levels of β-catenin as determined by Western blot analysis. b TCF4
was deleted in HCT116 and SW480 cells. The protein levels of TCF4 as
determined by Western blot analysis. c MTT cell proliferation assay performed
in β-catenin silencing HCT116 and SW480 cells treated with the indicated
concentrations of 5-Fu. d MTT cell proliferation assay performed in TCF4
deletion HCT116 and SW480 cells treated with the indicated concentrations of
5-Fu. e MTT cell proliferation assay performed in β-catenin silencing HCT116
and SW480 cells treated with the indicated concentrations of Oxa. f MTT cell
proliferation assay performed in TCF4 deletion HCT116 and SW480 cells
treated with the indicated concentrations of Oxa. *P< 0.05. (TIF 3961 kb)
Additional file 7: Regulation of CRC cell proliferation, chemoresistance
and Wnt/β-catenin signaling by CRNDE requires miR-181a-5p. a MTT cell
proliferation assay, b colony formation assay, c MTT cell proliferation assay
under the treatment of the indicated concentrations of 5-Fu or d Oxa, e
The protein levels of β-catenin and TCF4 as determined by Western blot
analysis, and f TOP/FOP luciferase activity assay performed in SW480 cells
transfected with siRNA targetting CRNDE or siR-control simultaneously
with miR-181a-5p or miR-control. *P < 0.05. (TIF 4563 kb)
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